EN | DE

Dr Joy Birkelbach

About

Joy Birkelbach studied pharmacy at the University of Greifswald. In her diploma thesis, Joy investigated the secondary metabolism of a shipworm symbiont, developed cultivation strategies and RT-qPCR protocols at the Institute of Pharmaceutical Biotechnology, University of Greifswald. In 2018, she obtained her diploma degree as well as her license to practice pharmacy. During her PhD studies, Joy worked with Myxobacteria and other gliding bacteria applying OSMAC-style cultivation approaches to trigger secondary metabolite production. To identify new natural products, she used comprehensive statistical analysis like MetaboScape and MZmine. Thus, she isolated and purified natural products with different chemical scaffolds using chromatographic methods like column and flash chromatography and HPLC. In order to characterise chemical, physical and structural properties, she applied spectrometric as well as spectroscopic methods, like MS and MS-MS analysis, and used NMR to elucidate the structure of those natural products.

Currently, Joy is involved in managing the myxobacterial extracts and fractions library generation aiming to streamline the discovery of chemically diverse natural products with anti-infective properties.
 


2024

Harnessing Gram-negative bacteria for novel anti-Gram-negative antibiotics

Birkelbach J, Seyfert C, Walesch S, Müller R (2024)

Microbial Biotechnology 17 (11)DOI: 10.1111/1751-7915.70032

Discovery of the Pendulisporaceae: An extremotolerant myxobacterial family with distinct sporulation behavior and prolific specialized metabolism

Garcia R, Popoff A, Bader C, Löhr J, Walesch S, Walt C, Boldt J, Bunk B, Haeckl F, Gunesch A, …, Bach T, Müller R (2024)

Chem 10: 1-20DOI: 10.1016/j.chempr.2024.04.019

2023

New Genetically Engineered Derivatives of Antibacterial Darobactins Underpin Their Potential for Antibiotic Development

Seyfert C, Müller A, Walsh D, Birkelbach J, Kany A, Porten C, Yuan B, Krug D, Herrmann J, Marlovits T, Hirsch A, Müller R (2023)

J. Med. Chem.DOI: 10.1021/acs.jmedchem.3c01660

New Genetically Engineered Derivatives of Antibacterial Darobac-tins Underpin their Potential for Antibiotic Development

Seyfert C, Müller A, Walsh D, Birkelbach J, Kany A, Porten C, Yuan B, Krug D, Herrmann J, Marlovits T, Hirsch A, Müller R (2023)

BookDOI: 10.26434/chemrxiv-2023-24tmj

The Disorazole Z Family of Highly Potent Anticancer Natural Products from Sorangium cellulosum: Structure, Bioactivity, Biosynthesis, and Heterologous Expression

Gao Y, Birkelbach J, Fu C, Herrmann J, Irschik H, Morgenstern B, Hirschfelder K, Li R, Zhang Y, Jansen R, Müller R (2023)

Microbiology SpectrumDOI: 10.1128/spectrum.00730-23

Fighting antibiotic resistance-strategies and (pre)clinical developments to find new antibacterials

Walesch S, Birkelbach J, Jézéquel G, Haeckl F, Hegemann J, Hesterkamp T, Hirsch A, Hammann P, Müller R (2023)

EMBO reports 24 (1)DOI: 10.15252/embr.202256033

2022

Expanding the Ajudazol Cytotoxin Scaffold: Insights from Genome Mining, Biosynthetic Investigations, and Novel Derivatives

Zeng H, Birkelbach J, Hoffmann J, Popoff A, Volz C, Müller R (2022)

Journal of natural productsDOI: 10.1021/acs.jnatprod.2c00637